Current treatment landscape of atopic dermatitis focusing on real-world evidence of dupilumab treatment
Authors:
- Celeste M. BoesjesCBCeleste M. Boesjes
- Lian F. van der GangLGLian F. van der Gang
- Roselie E. AchtenRARoselie E. Achten
- Daphne S. BakkerDBDaphne S. Bakker
- Lisa P. van der RijstLRLisa P. van der Rijst
- Coco C. DekkersCDCoco C. Dekkers
- Femke van WijkFWFemke van Wijk
- Marjolein S. de Bruin-WellerMBMarjolein S. de Bruin-Weller
- 2 November 2025
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Biological Therapy
- Vol. 25 (11) , 1171-1192
Abstract
Atopic dermatitis (AD) is a prevalent chronic inflammatory skin disorder and has a considerable impact on patients' quality of life. Dupilumab, the first biologic approved for moderate-to-severe AD, is a human monoclonal antibody targeting the interleukin (IL)-4 receptor α, thereby blocking both IL-4 and IL-13 signaling, key drivers of type 2 inflammation in AD. Its introduction has marked a paradigm shift in the management of AD and paved the way for future therapies. As real-world evidence on biologics and Janus kinase (JAK) inhibitors is rapidly emerging, comprehensive and up-to-date reviews are important. This review primarily summarizes real-world data on dupilumab, with a focus on its effectiveness and safety in clinical practice, highlighting recent findings and their implications for optimizing patient management. Real-world evidence consistently confirms the high effectiveness, favorable safety profile, and long-term treatment durability of dupilumab across various patient subgroups, including children, elderly, and patients with different underlying immune and genetic profiles. Additionally, dupilumab has demonstrated beneficial effects in patients with comorbid asthma and food allergies. Emerging data further support its potential safety during pregnancy, breastfeeding, and (non-)live vaccinations. Dose tapering is often successful and lowers the socio-economic impact of dupilumab.Keywords
This publication has 276 references indexed in Scilit:
- Dupilumab-Associated Lymphoid Reactions in Patients With Atopic DermatitisJAMA Dermatology, 2023
- Efficacy and Safety of Tralokinumab in Adolescents With Moderate to Severe Atopic DermatitisJAMA Dermatology, 2023
- Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic DermatitisJAMA Dermatology, 2023
- Association of Serum Dupilumab Levels at 16 Weeks With Treatment Response and Adverse Effects in Patients With Atopic DermatitisJAMA Dermatology, 2022
- Dupilumab Drug Survival and Associated Predictors in Patients With Moderate to Severe Atopic DermatitisJAMA Dermatology, 2022
- Systemic Immunomodulatory Treatments for Atopic DermatitisJAMA Dermatology, 2022
- Treatment Outcomes Associated With Dupilumab Use in Patients With Atopic DermatitisJAMA Dermatology, 2022
- Association Between Atopic Eczema and Cancer in England and DenmarkJAMA Dermatology, 2020
- Comparison of Tightly Controlled Dose Reduction of Biologics With Usual Care for Patients With PsoriasisJAMA Dermatology, 2020
- Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic DermatitisJAMA Dermatology, 2020